2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells
Supports Brain and Nervous System Health
That is why searches like FDA status CJC-1295 Ipamorelin compounding 2026 need a careful answer
Bravenboer B, Kappelle AC, Hamers FP, van Buren T, Erkelens DW, Gispen WH
E., Kim, S
Hershey Medical Center with 60 adults (ages 30-79): 250 mg or 1,000 mg daily for 6-7 months Whole Blood: 30% increase Red Blood Cells: 35% increase Buccal Cells: 260% increase Taking 1,000 mg daily significantly boosts antioxidants, promoting better health and a stronger immune system
